Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Can...
April 17 2018 - 8:00AM
Business Wire
Lm platform targets common mutations
in tumor driver genes
Advaxis, Inc. (NASDAQ: ADXS), a late-stage
biotechnology company focused on the discovery, development and
commercialization of immunotherapy products, announces the
presentation of ADXS-HOT preclinical data in a poster discussion
entitled “Targeting Shared Hotspot Cancer Mutations with a Listeria
monocytogenes Immunotherapy Induce Potent Anti-Tumor Immunity” at
the American Association for Cancer Research (AACR) Annual Meeting
underway in Chicago. The discussion, held yesterday, was led by
Daniel O. Villarreal, Ph.D., Principal Scientist at Advaxis.
The ADXS-HOT franchise leverages the Company’s proprietary Lm
Technology to target common mutations in tumor driver genes.
This study’s objective was to identify and target common (public
or shared) mutations (hotspots) and to determine if the ADXS-HOT
platform could effectively target those hotspots and control tumor
growth. Results indicate that ADXS-HOT could achieve this in
preclinical models against single and multi-target constructs. The
full abstract is available here:
https://www.advaxis.com/wp-content/uploads/2018/04/HOT-AACR-Abstract-Final-2018.pdf
“The results of this preclinical work with ADXS-HOT represent an
exciting opportunity that may allow us to develop disease-specific
immunotherapies that have the potential to be effective against
multiple targets, capable of generating high-avidity T cells
against shared of public mutations, as well as multiple proprietary
highly immunogenic cancer-testes and oncofetal antigens for
multiple tumor types,” said Robert G. Petit, Ph.D., Executive Vice
President and Chief Scientific Officer of Advaxis. “Additionally,
the results show increased functionality and resiliency in CD8 T
cells upon restimulation, indicating the potential not only to
increase the number and frequency of CD8 T cells, but to strengthen
them.”
About ADXS-HOT
ADXS-HOT leverages the Company’s proprietary Lm technology to
target common “hotspot” mutations. ADXS-HOT products are designed
to target acquired shared or “public” mutations in tumor driver
genes along with cancer-testes and oncofetal tumor-associated
antigens that are shared by multiple patients. Although ADXS-HOT
has not been tested in patients, in theory, products would be
designed to treat all patients with a particular type of cancer,
without the need for pre-treatment testing, biopsy, DNA sequencing
or diagnostic testing.
About Advaxis, Inc.
Advaxis, Inc. is a late-stage biotechnology company focused on
the discovery, development and commercialization of proprietary
Lm-based antigen delivery products. These immunotherapies are based
on a platform technology that utilizes live attenuated Listeria
monocytogenes (Lm) bioengineered to secrete antigen/adjuvant fusion
proteins. These Lm-based strains are believed to be a significant
advancement in immunotherapy as they integrate multiple functions
into a single immunotherapy and are designed to access and direct
antigen presenting cells to stimulate anti-tumor T cell immunity,
activate the immune system with the equivalent of multiple
adjuvants, and simultaneously reduce tumor protection in the tumor
microenvironment to enable the T cells to eliminate tumors. Advaxis
has four franchises in various stages of clinical and preclinical
development: HPV-associated cancers, neoantigen therapy, hotspot
cancer antigens and prostate cancer.
To learn more about Advaxis, visit www.advaxis.com and connect
on Twitter, LinkedIn, Facebook, and YouTube.
Advaxis Forward-Looking Statement
This press release contains forward-looking statements,
including, but not limited to, statements regarding Advaxis’
ability to develop and commercialize the next generation of cancer
immunotherapies, and the safety and efficacy of Advaxis’
proprietary immunotherapies. These forward-looking statements are
subject to a number of risks including the risk factors set forth
from time to time in Advaxis’ SEC filings including, but not
limited to, its report on Form 10-K for the fiscal year ended
October 31, 2017, and on Form 10-Q for the quarter ended January
31, 2018, which are available at www.sec.gov.
Any forward-looking statements set forth in this presentation
speak only as of the date of this presentation. We do not intend to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof other than as
required by law. You are cautioned not to place undue reliance on
any forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180417005616/en/
Company:Advaxis, Inc.Noelle Heber, 609-250-7575Sr.
Director Corporate Communications and Government
AffairsHeber@advaxis.comorInvestors:LHA Investor
RelationsMiriam Weber Miller, 212-838-3777mmiller@lhai.com
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Ayala Pharmaceuticals (CE) (USOTC:ADXS)
Historical Stock Chart
From Sep 2023 to Sep 2024